Annexon Inc. (ANNX) Financial Statements (2024 and earlier)
Company Profile
Business Address |
1400 SIERRA POINT PARKWAY BRISBANE, CA 94005 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
---|---|---|---|---|---|---|---|
ASSETS | |||||||
Current Assets | |||||||
Cash, cash equivalents, and short-term investments, including: | 259,700 | 242,700 | 242,700 | 351,200 | |||
Cash and cash equivalents | 225,110 | 140,020 | 74,843 | 268,565 | |||
Short-term investments | 34,606 | 102,637 | 167,872 | 82,641 | |||
Other undisclosed cash, cash equivalents, and short-term investments | (16) | 43 | (15) | (6) | |||
Prepaid expense | 1,464 | 1,433 | 1,513 | 1,763 | |||
Other current assets | 63 | 203 | 463 | 3 | |||
Other undisclosed current assets | 2,633 | 3,762 | 3,017 | 1,045 | |||
Total current assets: | 263,860 | 248,098 | 247,693 | 354,011 | |||
Noncurrent Assets | |||||||
Operating lease, right-of-use asset | 18,009 | 19,128 | 20,333 | ||||
Property, plant and equipment | 14,773 | 16,838 | 17,848 | 1,935 | |||
Restricted cash and investments | 1,032 | 1,032 | 1,166 | ||||
Total noncurrent assets: | 33,814 | 36,998 | 39,347 | 1,935 | |||
TOTAL ASSETS: | 297,674 | 285,096 | 287,040 | 355,946 | |||
LIABILITIES AND EQUITY | |||||||
Liabilities | |||||||
Current Liabilities | |||||||
Accounts payable and accrued liabilities | 15,722 | 20,864 | 20,403 | 10,231 | |||
Accounts payable | 5,487 | 7,416 | 11,153 | 3,734 | |||
Accrued liabilities | 10,235 | 13,448 | 9,250 | 6,497 | |||
Deferred rent credit | 391 | ||||||
Other liabilities | 41 | 180 | 139 | ||||
Other undisclosed current liabilities | 2,165 | 1,316 | 1,202 | ||||
Total current liabilities: | 17,928 | 22,360 | 21,744 | 10,622 | |||
Noncurrent Liabilities | |||||||
Long-term debt and lease obligation: | 33,387 | ||||||
Liabilities, other than long-term debt | 29,190 | 31,542 | 1,046 | ||||
Deferred rent credit | 1,046 | ||||||
Operating lease, liability | 29,190 | 31,542 | 33,387 | ||||
Other undisclosed noncurrent liabilities | (33,387) | ||||||
Total noncurrent liabilities: | 29,190 | 31,542 | 33,387 | 1,046 | |||
Total liabilities: | 47,118 | 53,902 | 55,131 | 11,668 | |||
Equity | |||||||
Equity, attributable to parent | 250,556 | 231,194 | 231,909 | 344,278 | |||
Common stock | 78 | 48 | 39 | 38 | |||
Additional paid in capital | 823,029 | 669,780 | 528,365 | 510,309 | |||
Accumulated other comprehensive loss | (52) | (372) | (180) | (77) | |||
Accumulated deficit | (572,499) | (438,262) | (296,315) | (165,992) | |||
Total equity: | 250,556 | 231,194 | 231,909 | 344,278 | |||
TOTAL LIABILITIES AND EQUITY: | 297,674 | 285,096 | 287,040 | 355,946 |
Income Statement (P&L) ($ in thousands)
6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
---|---|---|---|---|---|---|
Revenues (Sublease Income) | 2,000 | 1,600 | 100 | |||
Gross profit: | 2,000 | 1,600 | 100 | |||
Operating expenses | (143,723) | (145,599) | (130,713) | (63,469) | ||
Other undisclosed operating loss | (2,000) | (1,600) | (100) | |||
Operating loss: | (143,723) | (145,599) | (130,713) | (63,469) | ||
Nonoperating income (Other Nonoperating income) | 57 | |||||
Loss from continuing operations before equity method investments, income taxes: | (143,723) | (145,599) | (130,713) | (63,412) | ||
Other undisclosed income from continuing operations before income taxes | 277,960 | 287,546 | 390 | |||
Income (loss) from continuing operations: | 134,237 | 141,947 | (130,323) | (63,412) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (130,323) | (63,412) | |
Net income (loss): | 134,237 | 141,947 | (130,323) | (63,412) | ||
Other undisclosed net loss attributable to parent | (268,474) | (283,894) | ||||
Net loss attributable to parent: | (134,237) | (141,947) | (130,323) | (63,412) | ||
Preferred stock dividends and other adjustments | (705) | |||||
Other undisclosed net loss available to common stockholders, basic | (6,219) | |||||
Net loss available to common stockholders, diluted: | (134,237) | (141,947) | (130,323) | (70,336) |
Comprehensive Income ($ in thousands)
6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
---|---|---|---|---|---|---|
Net income (loss): | 134,237 | 141,947 | (130,323) | (63,412) | ||
Other comprehensive income (loss) | 320 | |||||
Other undisclosed comprehensive income | ||||||
Comprehensive income (loss): | 134,557 | 141,947 | (130,323) | (63,412) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (268,474) | (284,086) | (103) | 3 | ||
Comprehensive loss, net of tax, attributable to parent: | (133,917) | (142,139) | (130,426) | (63,409) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.